Publication date: Jun 02, 2025
We conducted a cost analysis of implementing a randomized controlled trial that proved the effectiveness of a community health worker (CHW) facilitated weight loss intervention among South Asian patients with prediabetes receiving care at primary care practices in New York City. South Asians have a high prevalence of diabetes, but no study to date has evaluated the cost of implementing an evidence-based lifestyle intervention in this population. Cost estimates are necessary for an intervention’s adoption and scale-up. The first wave of the intervention was implemented in-person, followed by two waves implemented remotely during the COVID-19 pandemic. We estimated the implementation, intervention, and adaptation costs and the costs by each wave of implementation, by applying the Gold et al. ‘s economic framework and ERIC discrete implementation strategy compilation Costs were calculated from the perspective of a health care payer, public health agency, or health care system. The CHW intervention included group education sessions over six months. For each wave, we separately estimated the total cost, cost per practice, and cost when implemented at only one practice. Using the Bureau of Labor Statistics salary estimates, we calculated the national average (mean salary) and lower (25th percentile salary) and upper (75th percentile salary) bounds. The average total 6-month implementation costs over 3 waves, each targeting seven practices was $215,420 (range: $158,620-$257,020). Program staff salaries comprised > 93% of total costs. Adaptation cost was nearly 1/3 of start-up costs. On average, implementation at one practice would cost twice as much as the per-practice costs when implemented simultaneously at seven practices in a wave, due to spread of start-up costs across multiple sites. Staff salaries comprise most of the budget to implement such an intervention. It is most efficient for an agency to implement this intervention across several practices simultaneously. Decision-makers will need to evaluate relative costs and effectiveness of other options to achieve weight loss in a minority community with constrained resources. GOV: This study was registered on June 15, 2017 at https://www. gov as NCT03188094. https://clinicaltrials. gov/ct2/show/NCT03188094 .
Open Access PDF
Concepts | Keywords |
---|---|
Clinicaltrials | Cost analysis |
Diabetes | Diabetes prevention |
June | Implementation costs |
Nct03188094 | |
Nyc |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | weight reduction |
disease | IDO | intervention |
disease | MESH | prediabetes |
disease | MESH | lifestyle |
disease | MESH | COVID-19 pandemic |
drug | DRUGBANK | Gold |
drug | DRUGBANK | Etodolac |
drug | DRUGBANK | Etoperidone |
pathway | REACTOME | Reproduction |
drug | DRUGBANK | Coenzyme M |
disease | MESH | diabetes mellitus |
drug | DRUGBANK | Metformin |
disease | MESH | limited English proficiency |
disease | IDO | site |